RT @Janetbirdope: Certrolizumab pegol decreases uveitis in open label study of SpA with past uveitis and HLAB27 group enriched for recurren…
Tweet Content
Certrolizumab pegol decreases uveitis in open label study of SpA with past uveitis and HLAB27 group enriched for recurrence. Pre and post Rx rates of uveitis were compared. 80% reduction of uveitis but uncontrolled and unblinded. #ACR #ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On